Telcon RF Pharmaceutical텔콘RF제약
200230 · KOSDAQ · ₩200230 · 텔콘RF제약
₩1,992▼ ₩33 (1.63%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 35.0% | 23.6% | 27.2% | 26.4% | 20.4% | 24.1% |
| Operating margin | 0.6% | 1.7% | −0.2% | 2.7% | −14.6% | −7.2% |
| Net margin | −28.3% | −26.5% | −69.5% | 38.3% | −151.2% | −61.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +43.1% | +14.0% | +4.3% | +30.5% | −26.5% | — |
| Operating income growth | −46.3% | +1,118.6% | −107.3% | +123.8% | −48.2% | — |
| Net income growth | −52.6% | +56.5% | −289.3% | +133.0% | −82.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −19.2% | −12.0% | −28.1% | 14.7% | −44.1% | −21.7% |
| Return on assets | −18.5% | −7.4% | −18.0% | 10.7% | −29.3% | −13.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 88.2% | 44.0% | 84.7% | 33.8% | 41.7% | 57.6% |
| Net debt to equity | 41.0% | 5.7% | 61.8% | 17.1% | 22.7% | 28.9% |
| Current ratio | 89.6% | 124.8% | 37.3% | 94.5% | 67.4% | 62.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Telcon RF Pharmaceutical / 텔콘RF제약 / 200230 / KRX:200230
Source: KRX statistical information